Third Arc Bio logo
Third Arc Bio logo

Third Arc Bio

thirdarcbio.com
thirdarcbio.com • Venture - Series Unknown 2024 • 201-500 employees • Founded 2021 • Startup • New
Venture - Series Unknown 2024 • 201-500 employees • Founded 2021 • Startup • New
Actively hiring
Immunology & Inflammation Therapeutics
Oncology Therapeutics
Health Care
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$72.5M
1 round on record
Latest round
$72.5M
Venture round · Jul 2024 · 2 yr ago
Team
201-500
employees, estimated range
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
0/100
no fresh signals
Funding rounds
RoundDateAmountInvestorsSource
Venture round Jul 2024 $72.5M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Third Arc Bio, Inc. sec
Founders and leadersfrom filings, registers and the company's site
Joseph ErhardtExecutive OfficerSEC Form D
Peter LebowitzExecutive Officer, DirectorSEC Form D
Similar startupsby what they do, their industry and backers
Cullinan Therapeutics
Committed to developing high-impact and differentiated therapies, with a focus on building a robust autoimmune disease and cancer pipeline…
Ditto Bio
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
TwoStep11-50 employees
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
AlixiaVenture round $1.8M · 2 yr ago • Founded 2022
Targeting the Tumor Ecosystem to address cancer drug resistance and improve patients’ lives.
Coultreon Biopharma51-200 employees
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
Octagon TherapeuticsVenture round $11M · 2 yr ago • Founded 2016 • 11-50 employees
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…

Overview

Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases.

People

Joseph Erhardt
Executive Officer
SEC Form D
Peter Lebowitz
Executive Officer, Director
SEC Form D
Arjun Goyal
Director
SEC Form D
Otello Stampacchia
Director
SEC Form D
Francesco Draetta
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove

Financials

Total raised
$72.5M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2024 $72.5M Details